PRMT7

Across TCGA pan-cancer cohorts, PRMT7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRMT7 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher PRMT7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRMT7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LGG, UCEC, and CHOL are the cancer types where PRMT7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.195	0.845	<.001	12	view →
UCEC	OS	Median	II,III,IV	1.000	0.465	.032	8	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	DFS	Median	All	0.213	0.676	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRMT7–LGG (DFS)

Open the LGG breakdown →